ReCode Therapeutics Appoints Nicholas P. France, M.D., as Senior Vice President of Clinical Development

Sept. 27, 2021 12:00 UTC



MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)-- ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Nicholas P. France, M.D., MRCPCH, as senior vice president, clinical development. In this role, Dr. France will lead all clinical and regulatory activities and serve as a key member of the executive leadership team.

“Nick has had an impressive career successfully leading clinical and regulatory activities for novel therapeutics at all stages of development,” said David Lockhart, Ph.D., CEO and President, ReCode Therapeutics. “He joins our team during an important period of growth as we work to rapidly advance our two lead programs for primary ciliary dyskinesia and cystic fibrosis into the clinic, while we also maximize our LNP delivery platform. We are excited to have him on board and look forward to his leadership as we pursue our mission to develop disease-modifying genetic medicines that can offer better outcomes for patients with unmet medical needs.”

Dr. France is an accomplished rare disease clinical drug developer with extensive clinical, regulatory and business development expertise across all phases of development. He previously served as vice president and head of clinical research at ESCAPE Bio, where he helped lead the transformation of the company from a preclinical to a clinical organization and had responsibility for all aspects of global clinical development and translational medicine. Prior to ESCAPE, Dr. France held positions of increasing responsibility in global biopharma organizations with a focus on developing clinical and regulatory strategy and building high performing clinical groups in emerging and early-stage biotech companies. He was senior director, clinical development for neurosciences and rare diseases with Roivant Sciences and Axovant Sciences, and executive director, clinical development at Strongbridge Biopharma. Other prior roles included global clinical program director at CSL Behring, and clinical development director, neurosciences and rare diseases at GlaxoSmithKline. During his career, Dr. France has successfully led a number of clinical programs through regulatory meetings for pivotal stage studies and has served in clinical leadership roles on the development of several assets that achieved regulatory approval including migalastat, AFSTYLA and Retigabine. He currently serves as a scientific medical advisory board member for the INADCure Foundation. He earned a B.S. in pharmacology from King’s College London (University of London) in the U.K. and his M.D. from the University of Warwick Medical School (U.K.) after which he trained in Pediatrics in London with a focus on Intensive Care Medicine. Dr. France is also a member of the Royal College of Pediatrics and Child Health.

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit and follow us on Twitter @ReCodeTx and LinkedIn.


Media Contact:
Will Zasadny
Canale Communications, Inc.
(619) 961-8848

Investor Contact:
Sarah McCabe
Stern Investor Relations


Source: ReCode Therapeutics

Back to news